HeartFlow plans to raise $300m in an IPO, seeking a $1.46bn valuation. The AI-based CAD platform developer filed with the SEC to go public on Nasdaq under ‘HTFL’. Their Plaque Analysis tool, FDA-cleared in 2022, targets arterial plaque buildup risks, estimating a $5bn US market opportunity.

HeartFlow’s profits rose to $125.8m in 2024, up 44% from 2023. Q1 2025 saw a 39% increase to $37.2m. The company’s next-gen Plaque Analysis tool, launched in 2024, works alongside FFRCT to analyze blockages on blood flow, FDA-cleared in 2014.

The medtech IPO season is strong, with HeartFlow aiming to raise $300m. Other companies like Beta Bionics, Medtronic, and Kestra Medical Technologies are also entering the IPO market. Carlsmed, following a 97% revenue rise in 2023, announced plans for a Nasdaq listing in June.

Read more at Yahoo Finance: HeartFlow sets sights on $300m IPO